Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure Does unbound drug and Pgp transport predict CNS exposure?

Xenobiotica

Volumn 39, Issue 9, 2009, Pages 687-693

  He, H ^a   Lyons, K A ^a   Shen, X ^a   Yao, Z ^a   Bleasby, K ^a   Chan, G ^a   Hafey, M ^a   Li, X ^a   Xu, S ^a   Salituro, G M ^a   Cohen, L H ^a   Tang, W ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cerebrospinal fluid (CSF); Liquid chromatography tandem mass spectrometry (LC MS MS); P glycoprotein transporter (Pgp); Plasma protein binding

Indexed keywords

GLYCOPROTEIN P; DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DIALYSIS; DRUG BLOOD LEVEL; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MALE; MOUSE; NONHUMAN; PLASMA PROTEIN BINDING; PREDICTION; PROTEIN TRANSPORT; TANDEM MASS SPECTROMETRY; TRANSGENIC MOUSE; WILD TYPE; ANIMAL; BLOOD; C57BL MOUSE; CELL LINE; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; MOUSE MUTANT; TRANSPORT AT THE CELLULAR LEVEL;

MUS;

ANIMALS; BIOLOGICAL TRANSPORT; CELL LINE; CENTRAL NERVOUS SYSTEM; CHROMATOGRAPHY, LIQUID; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; P-GLYCOPROTEIN; PHARMACEUTICAL PREPARATIONS; TANDEM MASS SPECTROMETRY;

EID: 70350516326     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250903015402     Document Type: Article

References (10)

1. De Lange ECM. (2004). Potential role of ABC transporters as a detoxi- fication system at blood-CSF barriers. Adv Drug Deliv Rev 56:1793-1809
2. Kalvass JC, Maurer TS. (2002). Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm. Drug Disposit 23: 327-338
3. Kalvass JC, Maurer TS, Pollack GM. (2007). Use of plasma and brain unbound to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo P-glycoprotein efflux ratios. Drug Metab Disposit 35: 660-666
4. Lin JH. (2004). How significant is the role of P-glycoprotein in drug absorption and brain uptake. Drug Today 40:5-22.
5. Lin JH. (2008). CSF as surrogate for assessing CSF exposure: an industrial perspective. Curr Drug Metab 9:46-59.
6. Maurer TS, DeBartolo DB, Tess DA, Obach SO. (2005). Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab Disposit 33:175-181
7. Ohe T, Sato M, Tanaka S, Fujino N, Hata F, Shibata Y, Kanatani A, Fukami F, Yamazaki M, Chiba M, Ishii Y. (2003). Effect of P-glycoprotein-mediated effl ux on cerebrospinal fluid/plasma concentration ratio. Drug Metab Disposit 31:1251-1254.
8. Schinkel AH, Smit JJM, Van Tellingen O, Beijnen JH, Wagenaar E, Vand Deemter, Mol CAMM, der Valk V, Robanus-Maandag EC, Te Riele HPJ, Berns AJM, Borst P. (1994). Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in blood-brain barrier and increased sensitivity to drugs. Cell 77:491-502.
9. Street JA, Hemworth BA, Roach AG, Day MD. (1979). Tissue levels of several radiolabelled beta-adreno receptor antagonists after intravenous administration in rats. Arch Int Pharmacodyn Ther 237:180-190
10. Summerfield SG, Stevens AJ, Cutler L, Osuma MDC, Hammond B, Tang SP, Hersey TA, Spalding DJ, Jeffrey P. (2006). Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux and free fractions in blood and brain. J Pharmacol Exp Ther 316:1282-1290